Just a month after it raised a funding round led by California’s Kern Venture Group, Halifax medtech startup MIMOSA Diagnostics is heading to Chicago in August to compete in the North American finals of the AI Healthtech Innovation Challenge.

Founded by Dr. Karen Cross, a plastic surgeon, and General Leung, a magnetic resonance researcher at the University of Toronto, MIMOSA has developed technology to more quickly diagnose bedsores and similar wounds via a process called tissue oximetry, which essentially uses light to measure tissue health.

The company placed first in the Atlantic division this week, besting runners-up Brightlight Health and ResolveHD. Brightlight sells AI tools for patient intake and management to enterprise clients in the healthcare space, while ResolveHD has developed an AI system that uses natural language processing to read and clean up disorganized medical records.

When MIMOSA pitches in Chicago on Aug. 6 and 7, the presentation will be watched by representatives from major healthcare providers, insurers and technology companies.

Last month’s capital raise, the amount of which was not disclosed, included funding from Kindling Venture Partners, another California company, Vancouver’s Spring Impact Capital, Toronto-based Raspberry Investment Corporation and returning investors.